by Dan Roberts June 2013 INTRODUCTION This is a summary of reports about significant research and development in the field of macular degeneration and related diseases presented since June 2012 and May 2013. I will briefly describe the conclusions of 77 studies that have been presented in the areas of therapy, prevention, technology, nutrition and [Read More]
Tag: Lucentis
Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration
(Updated 3/12/22) A substance in the body called Vascular Endothelial Growth Factor (VEGF) is responsible for the growth of new blood vessels. It promotes this growth by stimulating the endothelial cells, which form the walls of the vessels and transport nutrients and oxygen to the tissues. Evidence shows that when the retinal pigment epithelial (RPE) [Read More]
Summary of Research and Developments in Macular Degeneration, 2010-2011
by Dan Roberts June 19, 2011 Introduction Since 2006, I have done my best to condense the high points of the previous year’s macular degeneration research into a single report that is concise and understandable for the layperson. I do so, because I understand first hand how important it is to be aware of everything [Read More]
Summary of Research and Developments in Macular Degeneration: 2009-2010
by Dan Roberts June 10, 2010 Introduction If I were to describe the past twelve months in a word, it would be “progress.” No spectacular breakthroughs have occurred during that time to make big news in the AMD world, but a lot of persistent work has been reaping promising results. moving us ever closer to [Read More]
Study Shows Lucentis and Avastin to be Equal
by Dan Roberts February 3, 2010 Investigators at Kaiser Permanente Southern California in Pasadena reported in the February 2010 issue of Ophthalmology that Avastin and Lucentis performed equally in recent testing. In an indirect comparison of the two drugs, study author Dr. Donald Fong and coauthors reviewed the records of 452 patients treated for wet [Read More]